https://www.fool.com/investing/high-growth/2007/05/21/novel-developments-at-neose.aspx
https://www.fool.com/investing/general/2007/05/09/a-hard-sell-at-north-pitt.aspx
https://www.fool.com/investing/high-growth/2007/05/22/savient-seems-set-for-success.aspx
https://www.fool.com/investing/high-growth/2007/05/15/risky-bet-orasure-thing.aspx
https://www.fool.com/investing/general/2007/04/30/thermogenesis-is-ready-to-heat-up.aspx
https://www.fool.com/investing/high-growth/2007/05/15/eyeing-isis.aspx
https://www.fool.com/investing/high-growth/2007/05/15/secret-cytori.aspx
https://www.fool.com/investing/high-growth/2007/05/16/biotech-prospects-for-a-sizzling-summer.aspx
https://www.fool.com/investing/dividends-income/2007/05/22/avandia-safety-concerns-weigh-down-glaxo.aspx
https://www.fool.com/investing/high-growth/2007/05/07/advanced-life-makes-progress.aspx
https://www.fool.com/investing/high-growth/2007/05/08/is-visicu-on-the-verge.aspx
https://www.fool.com/investing/high-growth/2007/05/03/altus-could-rise-to-new-heights.aspx
https://www.fool.com/investing/high-growth/2007/05/18/innovative-inovio.aspx
https://www.fool.com/investing/high-growth/2007/05/16/zymogenetics-is-poised-to-stop-bleeding.aspx
https://www.fool.com/investing/high-growth/2007/05/22/insites-vision-of-profits.aspx
https://www.fool.com/investing/high-growth/2007/05/04/taking-it-to-the-affymax.aspx
https://www.fool.com/investing/high-growth/2007/05/17/pozen-poised-for-profits.aspx
https://www.fool.com/investing/high-growth/2007/05/21/a-new-order-at-sequenom.aspx
https://www.fool.com/investing/high-growth/2007/04/30/vivus-revives-investor-interest.aspx
https://www.fool.com/investing/general/2007/05/16/nastech-nose-potential.aspx
https://www.fool.com/investing/high-growth/2007/05/02/consider-cortex.aspx
https://www.fool.com/investing/high-growth/2007/04/27/monitoring-shares-of-visicu.aspx
https://www.fool.com/investing/high-growth/2007/05/15/on-the-threshold-at-sonus.aspx
https://www.fool.com/investing/high-growth/2007/05/09/scintillating-synta.aspx
https://www.fool.com/investing/general/2007/05/07/oscillating-oscient.aspx
https://www.fool.com/investing/high-growth/2007/05/02/an-eye-opening-potential-acquisition.aspx
https://www.fool.com/investing/high-growth/2007/05/14/investors-tire-of-inspire.aspx
https://www.fool.com/investing/high-growth/2007/05/22/coley-gets-a-cold-reception.aspx
https://www.fool.com/investing/high-growth/2007/05/07/critical-therapeutics-juncture.aspx
https://www.fool.com/investing/high-growth/2007/05/29/a-biotech-triple-play.aspx
https://www.fool.com/investing/high-growth/2007/05/15/a-heads-up-on-torreypines.aspx
https://www.fool.com/investing/high-growth/2007/05/17/javelin-is-right-on-target.aspx
https://www.fool.com/investing/high-growth/2007/05/16/waiting-on-memory-pharmaceuticals.aspx
https://www.fool.com/investing/high-growth/2007/05/02/heads-up-biotech-investors-chapter-2.aspx
https://www.fool.com/investing/high-growth/2007/05/01/a-weekly-planner-for-biotech-investors.aspx
https://www.fool.com/investing/high-growth/2007/05/17/picking-up-the-pace-at-cadence.aspx
https://www.fool.com/investing/high-growth/2007/05/15/a-tale-of-two-trials-at-ym-bio.aspx
https://www.fool.com/investing/value/2007/04/26/xenoport-soothes-investors-restless-hearts.aspx
https://www.fool.com/investing/high-growth/2007/05/03/heads-up-biotech-investors-version-30.aspx
https://www.fool.com/investing/high-growth/2007/05/18/ample-opportunities-for-alnylam.aspx
https://www.fool.com/investing/general/2007/04/27/detecting-an-opportunity-in-exact-sciences.aspx
https://www.fool.com/investing/high-growth/2007/05/23/cypress-bioscience-comes-full-circle.aspx
https://www.fool.com/investing/high-growth/2007/05/24/a-new-era-at-aeterna.aspx
https://www.fool.com/investing/high-growth/2007/05/04/on-deck-in-biotech.aspx
https://www.fool.com/investing/general/2007/05/14/a-weaker-amgen.aspx
https://www.fool.com/investing/high-growth/2007/04/26/dendreon-is-worth-a-shot.aspx
https://www.fool.com/investing/high-growth/2007/05/21/allos-aligned-for-success.aspx
https://www.fool.com/investing/high-growth/2007/05/22/an-emergent-opportunity.aspx
